Evidence map›Paper›PMID 36908898›Full record

ArticleAging brain2022

Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia.

Lorenzini Luigi, Ingala Silvia, Wottschel Viktor, Alle Meije Wink, Henk Jmm Mutsaerts, Haller Sven, Blennow Kaj, John T O'Brien, Frisoni B Giovanni, Chételat Gael and 10 more

Abstract read
In one paragraph

Article in Aging brain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lorenzini LuigiDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Ingala SilviaDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Wottschel ViktorDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Alle Meije WinkDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Henk Jmm MutsaertsDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Haller SvenCIMC - Centre d'Imagerie Médicale de Cornavin, Place de Cornavin 18, 1201 Genève, Switzerland.
Blennow KajDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden.
John T O'BrienDepartment of Psychiatry, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Box 189, Cambridge CB2 0QQ, UK.
Frisoni B GiovanniLaboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Chételat GaelUniversité de Normandie, Unicaen, Inserm, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood-and-Brain @ Caen-Normandie, Cyceron, 14000 Caen, France.
Payoux PierreDepartment of Nuclear Medicine, Toulouse CHU, Purpan University Hospital, Toulouse, France.
Martinez-Lage PabloCentro de Investigación y Terapias Avanzadas, Neurología, CITA-Alzheimer Foundation, San Sebastián, Spain.
Waldman AdamCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.
Wardlaw JoannaCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.
Ritchie CraigCentre for Dementia Prevention, The University of Edinburgh, Scotland, UK.
Juan Domingo GispertBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Pieter Jelle VisserDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Scheltens PhilipDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
Barkhof FrederikDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Betty M TijmsUniversitat Pompeu Fabra, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gray matter networks are altered with amyloid accumulation in the earliest stage of AD, and are associated with decline throughout the AD spectrum. It remains unclear to what extent gray matter network abnormalities are associated with hyperphosphorylated-tau (p-tau). We studied the relationship of cerebrospinal fluid (CSF) p-tau181 with gray matter networks in non-demented participants from the European Prevention of Alzheimer's Dementia (EPAD) cohort, and studied dependencies on amyloid and cognitive status. Gray matter networks were extracted from baseline structural 3D T1w MRI. P-tau181 and abeta were measured with the Roche cobas Elecsys System. We studied the associations of CSF biomarkers levels with several network's graph properties. We further studied whether the relationships of p-tau 181 and network measures were dependent on amyloid status and cognitive stage (CDR). We repeated these analyses for network properties at a regional level, where we averaged local network values across cubes within each of 116 areas as defined by the automated anatomical labeling (AAL) atlas. Amyloid positivity was associated with higher network size and betweenness centrality, and lower gamma, clustering and small-world coefficients. Higher CSF p-tau 181 levels were related to lower betweenness centrality, path length and lambda coefficients (all p < 0.01). Three-way interactions between p-tau181, amyloid status and CDR were found for path length, lambda and clustering (all p < 0.05): Cognitively unimpaired amyloid-negative participants showed lower path length and lambda values with higher CSF p-tau181 levels. Amyloid-positive participants with impaired cognition demonstrated lower clustering coefficients in association to higher CSF p-tau181 levels. Our results suggest that alterations in gray matter network clustering coefficient is an early and specific event in AD.

Indexed as

AmyloidBrain connectivityGray matter networksPreclinical AlzheimerTau

Identifiers

PMID36908898
PMCPMC9997148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.